# The Cooper Companies, Inc. (COO) Stock Analysis: Exploring a 30.51% Potential Upside

- Link: https://www.directorstalkinterviews.com/the-cooper-companies-inc-coo-stock-analysis-exploring-a-30-51-potential-upside/4121244759
- Published: 2026-03-16T11:17:52+00:00
- Author: Madison Wilson

Investors have their eyes on The Cooper Companies, Inc. (NYSE: COO) as it continues
to present intriguing opportunities within the healthcare sector. Specializing in
medical instruments and supplies, Cooper Companies operates through its prominent
segments: CooperVision and CooperSurgical. With a market capitalization of $13.64
billion, the company is a significant player in its industry, offering innovative
products ranging from contact lenses to women’s health care solutions.

Currently trading at $69.92, COO’s stock has experienced a slight dip of 0.02% recently.
However, the stock’s 52-week range of $64.32 to $84.98 highlights its volatility
and the opportunity for strategic investment. Analysts suggest a potential upside
of 30.51%, with a target price range between $73.00 and $103.00 and an average target
of $91.25. This substantial potential increase is a key factor drawing investor 
interest.

While the trailing P/E ratio is unavailable, Cooper Companies boasts a forward P/
E of 13.93. This figure, coupled with the company’s revenue growth of 6.20%, positions
it as a company with robust future earnings potential. Despite the absence of specific
PEG and price/book ratios, the company’s performance metrics provide some clarity.
Notably, the company reported an EPS of 2.01 and a return on equity of 4.87%, indicating
stable financial health and efficient use of equity.

Free cash flow stands at an impressive $367 million, suggesting that Cooper Companies
is capable of sustaining its operations and potentially pursuing growth initiatives
without relying heavily on external financing. However, the company does not currently
offer a dividend, as evidenced by a payout ratio of 0.00%. This could be a consideration
for investors seeking income-generating stocks.

The technical indicators paint a mixed picture. The 50-day moving average of $80.94
contrasts with the current price, suggesting recent downward pressure. Furthermore,
the RSI (14) at 33.11 indicates the stock may be approaching oversold conditions,
potentially setting the stage for a rebound. The MACD at -2.87, below the signal
line of -1.46, also suggests bearish momentum, yet this could present a buying opportunity
for those looking to capitalize on potential market corrections.

In terms of analyst sentiment, Cooper Companies has garnered 11 buy ratings, 7 hold
ratings, and only 1 sell rating. This indicates a generally positive outlook among
market analysts, reinforcing the company’s reputation as a strong player in the 
healthcare sector.

The Cooper Companies, Inc., founded in 1958 and headquartered in San Ramon, California,
continues to evolve with its dual focus on vision care and women’s health. The CooperVision
segment addresses common vision issues like myopia and astigmatism with its advanced
contact lenses, while CooperSurgical provides essential healthcare products and 
services, including fertility solutions and contraceptive devices.

With its strategic positioning in the healthcare industry and consistent financial
performance, The Cooper Companies, Inc. remains a compelling consideration for investors
looking to diversify their portfolio with a healthcare stock poised for potential
growth.

Share on:
